Evolution of ergosterol biosynthesis inhibitors as fungicidal against Candida

Microbial Pathogenesis

Volumn 48, Issue 1, 2010, Pages 35-41

  Ahmad, Aijaz ^a   Khan, Amber ^a   Manzoor, Nikhat ^a   Khan, Luqman A ^a  

^a JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

Author keywords

Candida; Ergosterol; Eugenol; Fluconazole; Methyl eugenol

Indexed keywords

ERGOSTEROL; EUGENOL; FLUCONAZOLE; METHYLEUGENOL; PYRROLE DERIVATIVE; STEROL 14ALPHA DEMETHYLASE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; DRUG STRUCTURE; DRUG TARGETING; FUNGICIDAL ACTIVITY; FUNGUS ISOLATION; IN VITRO STUDY; INHIBITION KINETICS; LIPOGENESIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA; ENZYME INHIBITORS; ERGOSTEROL; EUGENOL; MICROBIAL VIABILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

CANDIDA;

EID: 72149084112     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2009.10.001     Document Type: Article

References (30)

1. Anderson J.B. Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat Rev Microbiol 3 (2005) 547-556
2. Pauw de B.E., and Meunier F. The challenge of invasive fungal infection. Chemotherapy 45 Suppl. 1 (1999) 1-14
3. Shao P.L., Huang L.M., and Hsueh P.R. Recent advances and challenges in the treatment of invasive fungal infections. Int J Antimicrob Agents 30 (2007) 487-495
4. Vanden B.H., Dromer F., Improvisi I., Lozano-Chiu M., Rex J.H., and Sanglard D. Antifungal drug resistance in pathogenic fungi. Med Mycol 36 Suppl. 1 (1998) 119-128
5. Zhang A.Y., Camp W.L., and Elewski B.E. Advances in topical and systemic antifungals. Dermatol Clin 25 (2007) 165-183
6. Bohme A., and Karthaus M. Systemic fungal infections in patients with hematologic malignancies: indications and limitations of the antifungal armamentarium. Chemotherapy 45 (1999) 315-324
7. Bastert J., Schaller M., Korting H.C., and Evans E.G. Current and future approaches to antimycotic treatment in the era of resistant fungi and immunocompromised hosts. Int J Antimicrob Agents 17 (2001) 81-91
8. Francois I.E., Aerts A.M., Cammue B.P., and Thevissen K. Currently used antimycotics: spectrum, mode of action and resistance occurrence. Curr Drug Targets 6 (2000) 895-907
9. Gupta A.K., and Tomas E. New antifungal agents. Dermatol Clin 21 (2003) 565-576
10. Polak A. Mode of action of morpholine derivatives. Ann NY Acad Sci 544 (1988) 221-228
11. Lupetti A., Danesi R., Campa M., Del Tacca M., and Kelly S. Molecular basis of resistance to azole antifungals. Trends Mol Med 8 (2002) 76-81
12. Nguyen M.H., Peacock J.E., Morris Jr. A.J., Tanner D.C., Nguyen M.L., Snydman D.R., et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 100 (1996) 617-623
13. Pfaller M.A., Jones R.N., Messer S.A., Edmond M.B., and Wenzel R.P. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis 30 (1998) 121-129
14. Vanden B.H., Willemsens G., and Marichal P. Anti-Candida drugs-the biochemical basis for their activity. Crit Rev Microbiol (1987) 1557-1572
15. Arias A., Arevalo M.P., Andreu A., Rodriguez C., and Sierra A. Candida glabrata: in vitro susceptibility of 84 isolates to eight antifungal agents. Chemotherapy 42 (1996) 107-111
16. Fortun J., Lopez-San Roman A., Velasco J.J., Sanchez-Sousa A., De Vicente E., Nuno J., et al. Selection of Candida glabrata strains with reduced susceptibility to azoles in four liver transplant patients with invasive candidiasis. Eur J Clin Microbiol Infect Dis 16 (1997) 314-318
17. Venkateswarlu K., Denning D.W., and Kelly S.L. Inhibition and interaction of cytochrome P450 of Candida krusei with azole antifungal drugs. J Med Vet Mycol 35 (1997) 19-25
18. Baris O., Gulluce M., Sahin F., Ozer H., Kilic H., Ozkan H., et al. Biological activities of the essential oil and methanol extract of Achillea Biebersteinii Afan (Asteraceae). Turk J Biol 30 (2006) 65-73
19. Iwu M.W., Duncan A.R., and Okunji C.O. New antimicrobials of plant origin. In: Janick J. (Ed). Perspectives on new crops and new uses (1999), ASHS Press, Alexandria 457-462
20. Kelly S.L., Lamb D.C., Corran A.J., Baldwin B.C., and Kelly D.E. Mode of action and resistance to azole antifungal associated with the formation of 14a-methylergosta-8, 24 (28)-dien-3b, 6a-diol. Biochem Biophys Res Commun 207 (1995) 910-915
21. Beth A., Skaggs A., Warnock D.W., and Morrison C.J. Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis. Antimicrob Agents Chemother 44 (2000) 2081-2085
22. NCCLS. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard M27-A2 (2002), National Committee on Clinical Laboratory Standards, Wayne, PA pp. 30
23. Onyewu C., Blankenship J.R., Poeta M.D., and Heitman J. Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. Antimicrob Agents Chemother (2000) 956-964
24. Cruz M.C., Goldstein A.L., Blankenship J.R., Del Poeta M., Davis D., Cardenas M.E., et al. Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO J 21 (2002) 546-559
25. Sanglard D., Ischer F., Koymans L., and Bille J. Amino acid substitutions in the cytochrome P-450 lanosterol 14 alpha-demethylase (CYP51A1) from azole-resistant Candida albicans isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother 42 (1998) 241-253
26. White T.C. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14 alphademethylase in Candida albicans. Antimicrob Agents Chemother 41 (1997) 1488-1494
27. Sanglard D., Kuchler K., Ischer F., Pagani J.-L., Monod M., and Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 39 (1995) 2378-2386
28. Geber A., Hitchcock C.A., Swartz J.E., Pullen F.S., Marsden K.E., Kwon-Chung K.J., et al. Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrob Agents Chemother 39 (1995) 2708-2727
29. Situ H., and Bobek L.A. In vitro assessment of antifungal therapeutic potential of salivary histatin-5, two variants of histatin-5, and salivary mucin (MUC7) domain 1. Antimicrob Agents Chemother 44 (2000) 1485-1493
30. Christie M.S., Kenneth L.R., and David B.W. Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles. Toxicological Sci 97 1 (2007) 163-180